Jenfer Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-06-2024
- Paid Up Capital ₹ 0.10 M
as on 23-06-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 21.86%
(FY 2022)
- Profit 169.29%
(FY 2022)
- Ebitda 199.16%
(FY 2022)
- Net Worth 35.64%
(FY 2022)
- Total Assets 0.80%
(FY 2022)
About Jenfer Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Munish Aggarwal, Sunita, Varesh Khanna, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909HR2015PTC055567
- Company No.
055567
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2015
- Date of AGM
25 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Jenfer Biosciences Private Limited offer?
Jenfer Biosciences Private Limited offers a wide range of products and services, including Diclofenac, Diclofenac Potassium Tablets, Pain Relief Drugs & Pharmaceuticals, Aceclofenac.
Who are the key members and board of directors at Jenfer Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varesh Khanna  | Director | 26-May-2015 | Current |
| Munish Aggarwal | Director | 26-May-2015 | Current |
| Sunita | Director | 26-May-2015 | Current |
| Jitendra Roy | Director | 26-May-2015 | Current |
Financial Performance of Jenfer Biosciences.
Jenfer Biosciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 21.86% increase. The company also saw a substantial improvement in profitability, with a 169.29% increase in profit. The company's net worth Soared by an impressive increase of 35.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jenfer Biosciences?
In 2019, Jenfer Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vintas Pharmaceuticals Private LimitedActive 9 years 5 monthsMunish Aggarwal and Varesh Khanna are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jenfer Biosciences?
Unlock and access historical data on people associated with Jenfer Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jenfer Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jenfer Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
